Le Lézard
Classified in: Health
Subjects: NPT, AVO

Stand for Health Freedom Endorses Jonathan Emord for U.S. Senate


Stand for Health Freedom endorses Jonathan Emord for the U.S. Senate in Virginia.

CLIFTON, Va., Nov. 20, 2023 /PRNewswire/ -- On behalf of its 590,000 advocates worldwide, Stand for Health Freedom has endorsed Jonathan Emord for the U.S. Senate in Virginia. Emord, a renowned constitutional litigator who has defeated the Food and Drug Administration in federal court on constitutional grounds a record 8 times, expressed his gratitude for the endorsement: "It is my great honor to receive Stand for Health Freedom's endorsement. I have long respected this highly effective advocacy organization for its stalwart defender of individual liberty and health freedom."

Like Stand for Health Freedom, Emord has consistently advocated individual freedom of choice and opposed vaccine and mask mandates and centralized government control over health care.

Stand for Health Freedom (SHF) is a 501 (c)(4) nonprofit organization dedicated to informing and activating a grassroots movement to protect health and families nationwide. SHF's endorsement reads in part:

"Stand for Health Freedom supports candidates who make and support policy to protect and expand individual and family choice in matters of personal health. We believe Jonathan Emord will defend and expand these rights for Virginia residents."

About Jonathan Emord?
A renowned constitutional law and litigation expert, Jonathan Emord has successfully battled the federal bureaucracy for over 37 years. He holds the record for defeating the Food and Drug Administration on constitutional grounds, 8 times, more than any other attorney in American history. He has authored five critically acclaimed books on law and government. Together, with his wife Sheryl Emord and their twins Justice and Angelica, they call Clifton, Virginia home.

 

SOURCE Emord for VA


These press releases may also interest you

at 00:25
Zai Lab Limited and Innoviva Specialty Therapeutics today announced that China's National Medical Products Administration (NMPA) has approved Zai Lab's New Drug Application (NDA) for XACDURO® (sulbactam-durlobactam) for the treatment of...

19 mai 2024
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...

19 mai 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

19 mai 2024
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

19 mai 2024
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

19 mai 2024
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...



News published on and distributed by: